Related Experiment Video
Updated: Jun 9, 2025
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615
Cindy Bandala1, Donaciano Flores-Robles2, Pavel Sierra-Martínez2
1Laboratorio de Medicina Traslacional Aplicada a Neurociencias, Enfermedades Crónicas y Emergentes, Escuela superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico.
Introduction:
CD38 and BCMA are proteins expressed at high levels in multiple myeloma cells, so they are targets for the development of mono- or multispecific antibodies.
Areas Covered:
Patent US20240132615 describes anti-CD3/BCMA/CD38 trispecific antibodies and a method of treating relapsed/refractory multiple myeloma pharmaceutically. In vitro and preclinical results show that anti-CD3/BCMA/CD38 trispecific antibodies have stronger binding affinity and killing potency compared to daratumumab, isatuximab, and teclistamab antibodies.
Expert Opinion:
The trispecific structure and a silenced Fc are pharmaceutical advantages of the anti-CD3/BCMA/CD38 antibody for the treatment of relapsed or refractory multiple myeloma.
More Related Videos
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
